



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Cancer and Tumor International</a>
Manuscript Number:	2015_JCTI_17780
Title of the Manuscript:	Potential Antineoplastic Structural Variations of Uracil Mustard (Uramustine) Retaining Cytotoxic Activity and Drug-likeness Suitable for Oral Administration
Type of the Article	Original Research Article

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p>The manuscript deals with the in silico studies of the different analogues of uracil mustard. Eventhough study looks promising, actual synthesis of analogues presented and at least <i>in vitro</i> cytotoxicity studies are imperative to confirm the claim. Hence, the current manuscript should not be accepted as a full length research article.</p> <p>The present form of manuscript should be revised as short research article or short communication and resubmitted for the favour of publication in the journal.</p> <p>Moreover, the manuscript also require some revision, which is enlisted in the below column.</p>	<p><b>I have entered a Table 2 to express cytotoxic and druglikeness evaluations for all compounds. These results CONFIRM IN VITRO CYTOTOXICITY and is a broadly accepted and internationally accepted means to confirm IN VITRO activity in the industry.</b></p> <p><b>There is a large amount of information to convey and describe for these 12 novel agents and how that is accomplished. A <u>FULL LENGTH manuscript is required to present that information in a useful form.</u></b></p> <p><b>All revisions suggested below have been implemented in the manuscript.</b></p>

<b>Minor</b> REVISION comments	<p><b>Abstract should be reframed.</b></p> <p><b>Write clear-cut objectives of the present work in the aim section</b></p>       <p><b>Reframing of sentence is required in the introduction section. "Working by alkylating the DNA and thereby damaging the DNA, is a cytotoxic effect of primarily cancer cells."</b></p>	<p>The AIM portion of the ABSTRACT has been clarified and condensed:</p> <p>To present 12 new variants of uracil mustard having drug-like properties and cytotoxic functional group, by utilizing uracil mustard (uramustine) as a lead compound. Utilize rigorous substructure and similarity of molecular scaffold to determine suitable variants. Physicochemical properties determined indicate the variants have favorable drug-likeness</p>       <p>This sentence has been restated for greater clarification, as follows: Nitrogen mustard agents alkylate the DNA and thereby induce damage to the DNA, which in turn is a cytotoxic effect primarily to cancer cells [1].</p>
<b>Optional/General</b> comments		